Thus, the results of larger prospective studies such as VISION [29], comparing survival outcomes of patients receiving PSMA-RLT with those acquiring the best standard medical care, as well as the interesting results of the multicenter TheraP trial [8], should help to support the forthcoming implementation of this radionuclide therapy into the clinical treatment routine of patients with prostate cancer. Here, FOLH1 is linked to Familial prostate cancer.